Pancreatic Cancer Research

ResearcherShiga University of Medical ScienceActive in the last 2 years

Mamoru Takenaka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7308-4311; OpenAlex author ID A5080363683, A5121046216. Sources: OpenAlex.

Their work

Papers
32 (first author 10, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
93
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 3 papers · 2018: 6 papers · 2019: 3 papers · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 4 papers · 2024: 2 papers · 2025: 3 papers · 2026: 5 papers

Papers 32

  1. Mortality and cancer risk in patients with chronic pancreatitis in japan: insights into the importance of surveillance for pancreatic cancer. Co-author DOI 10.1007/s00535-025-02321-0↗
  2. Response to the letter to the editor regarding "Concealed pancreatic cancer in acute pancreatitis: Early MRCP and EUS surveillance improves prognosis and ident… First author DOI 10.1016/j.pan.2025.12.005↗
  3. Establishment of simple pancreatic ductal adenocarcinoma identification method: S100P measurement in duodenal fluid obtained during upper gastrointestinal endo… Co-author DOI 10.1016/j.pan.2025.12.020↗
  4. Comparative Study of Pathological and Imaging Findings in High-Grade Pancreatic Intraepithelial Neoplasia: A Multicenter Analysis by the Japan Study Group on E… Co-author DOI 10.1097/mpa.0000000000002710↗
  5. Impact of Stent Type on Surgical Outcomes in Pancreatic Cancer Patients Undergoing Preoperative Biliary Drainage. Last author DOI 10.1111/den.70229↗
  6. Multicenter Comparative Study of 6- and 10-mm Fully Covered Self-Expandable Metal Stents for Malignant Distal Biliary Obstruction During Neoadjuvant Chemothera… Co-author DOI 10.1002/jhbp.12157↗
  7. Prognostic Impact of Unplanned Total Pancreatectomy in Pancreatic Ductal Adenocarcinoma: A Retrospective Analysis. Co-author DOI 10.1002/jhbp.12176↗
  8. Concealed pancreatic cancer in acute pancreatitis: Early MRCP and EUS surveillance improves prognosis and identifies high-risk patients. First author DOI 10.1016/j.pan.2025.02.013↗
  9. Association of pancreatic atrophy patterns with intraductal extension of early pancreatic ductal adenocarcinoma: a multicenter retrospective study. Co-author DOI 10.1007/s00535-024-02149-0↗
  10. Early diagnosis of pancreatic cancer via pancreatic juice cytology with a cell-block method in a patient with altered anatomy Co-author DOI 10.1055/a-2317-0520↗
  11. Low-dose gemcitabine plus nab-paclitaxel versus standard-dose gemcitabine plus nab-paclitaxel in elderly patients with metastatic pancreatic cancer: A randomiz… Co-author DOI 10.1002/jgh3.12966↗
  12. Gastrojejunostomy versus endoscopic duodenal stent placement for gastric outlet obstruction in patients with unresectable pancreatic cancer: a propensity score… First author DOI 10.1007/s00464-022-09685-x↗
  13. Impact of Smad4 and p53 mutations on the prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemotherapy. First author DOI 10.1007/s10147-023-02396-w↗
  14. Benefits of pancreatic parenchymal endoscopic ultrasonography in predicting microscopic precancerous lesions of pancreatic cancer. Co-author DOI 10.1038/s41598-023-38920-1↗
  15. Efficacy of EUS-guided celiac plexus neurolysis in combination with EUS-guided celiac ganglia neurolysis for pancreatic cancer-associated pain: a multicenter p… Co-author DOI 10.1007/s10147-022-02160-6↗
  16. Utility of contrast-enhanced harmonic EUS for diagnosis of portal vein invasion by pancreatic cancer. Co-author DOI 10.4103/eus-d-21-00185↗
  17. Improved detection of liver metastasis using Kupffer-phase imaging in contrast-enhanced harmonic EUS in patients with pancreatic cancer (with video). Co-author DOI 10.1016/j.gie.2020.06.051↗
  18. Analysis of Progression Time in Pancreatic Cancer including Carcinoma In Situ Based on Magnetic Resonance Cholangiopancreatography Findings. Co-author DOI 10.3390/diagnostics11101858↗
  19. Partial Pancreatic Parenchymal Atrophy Is a New Specific Finding to Diagnose Small Pancreatic Cancer (≤10 mm) Including Carcinoma in Situ: Comparison with Loca… First author DOI 10.3390/diagnostics10070445↗
  20. Contrast-enhanced harmonic endoscopic ultrasonography for evaluating the response to chemotherapy in pancreatic cancer. Co-author DOI 10.1016/j.dld.2019.03.015↗
  21. Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrosp… First author DOI 10.2169/internalmedicine.2234-18↗
  22. Can Localized Stenosis of the Main Pancreatic Duct be a Predictive Factor for Early Detection of Pancreatic Cancer? Co-author DOI 10.5946/ce.2019.204↗
  23. Impact of avascular areas, as measured by contrast-enhanced harmonic EUS, on the accuracy of FNA for pancreatic adenocarcinoma. First author DOI 10.1016/j.gie.2017.05.052↗
  24. Outcomes of endoscopic biliary drainage in pancreatic cancer patients with an indwelling gastroduodenal stent: a multicenter cohort study in West Japan. Co-author DOI 10.1016/j.gie.2018.01.021↗
  25. Multicenter study of early pancreatic cancer in Japan. Co-author DOI 10.1016/j.pan.2017.11.007↗
  26. Pancreatic inflammation and atrophy are not associated with pancreatic cancer concomitant with intraductal papillary mucinous neoplasm. Co-author DOI 10.1016/j.pan.2017.12.007↗
  27. Multifocal cysts and incidence of pancreatic cancer concomitant with intraductal papillary mucinous neoplasm. Co-author DOI 10.1016/j.pan.2018.04.005↗
  28. Alleviating Pancreatic Cancer-Associated Pain Using Endoscopic Ultrasound-Guided Neurolysis. First author DOI 10.3390/cancers10020050↗
  29. Smoking Status and the Incidence of Pancreatic Cancer Concomitant With Intraductal Papillary Mucinous Neoplasm. Co-author DOI 10.1097/mpa.0000000000000761↗
  30. Association between the Risk Factors for Pancreatic Ductal Adenocarcinoma and Those for Malignant Intraductal Papillary Mucinous Neoplasm. First author DOI 10.1159/000481234↗
  31. EUS-Guided Pancreatic Duct Drainage for Repeat Pancreatitis in a Patient with Pancreatic Cancer. First author DOI 10.1159/000481238↗
  32. Effectiveness of endoscopic self-expandable metal stent placement for afferent loop obstruction caused by pancreatic cancer recurrence after pancreaticoduodene… Co-author DOI 10.1007/s12328-015-0556-0↗

Closest collaborators

The 25 strongest of 93 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masatoshi Kudo · 18 shared papers, 2017–2026 · strength 2.35
  2. Kentaro Yamao · 16 shared papers, 2017–2026 · strength 2.13
  3. Kosuke Minaga · 16 shared papers, 2017–2025 · strength 1.83
  4. Ken Kamata · 14 shared papers, 2017–2025 · strength 1.52
  5. Masayuki Kitano · 11 shared papers, 2018–2026 · strength 1.50
  6. Ippei Matsumoto · 8 shared papers, 2017–2026 · strength 1.05
  7. Atsuhiro Masuda · 7 shared papers, 2017–2026 · strength 0.93
  8. Atsushi Nakai · 8 shared papers, 2017–2023 · strength 0.74
  9. Arata Sakai · 5 shared papers, 2015–2025 · strength 0.65
  10. Hidekazu Tanaka · 5 shared papers, 2019–2024 · strength 0.63
  11. Keiji Hanada · 4 shared papers, 2018–2026 · strength 0.60
  12. Takuya Ishikawa · 2 shared papers, 2025–2026 · strength 0.57
  13. Yuzo Kodama · 3 shared papers, 2023–2025 · strength 0.54
  14. Takao Ohtsuka · 3 shared papers, 2018–2026 · strength 0.53
  15. Takashi Kobayashi · 6 shared papers, 2015–2024 · strength 0.52
  16. Yasuo Otsuka · 3 shared papers, 2022–2024 · strength 0.52
  17. Takeshi Ogura · 3 shared papers, 2022–2026 · strength 0.50
  18. Keitaro Sofue · 5 shared papers, 2017–2024 · strength 0.48
  19. Hirochika Toyama · 5 shared papers, 2017–2024 · strength 0.48
  20. Noboru Ideno · 2 shared papers, 2026 · strength 0.46
  21. Ryota Nakano · 2 shared papers, 2024–2025 · strength 0.41
  22. Hiroki Kawashima · 1 shared paper, 2026 · strength 0.36
  23. Takashi Tamura · 2 shared papers, 2023–2026 · strength 0.35
  24. Yoshifumi Takeyama · 4 shared papers, 2017–2022 · strength 0.33
  25. Masakatsu Tsurusaki · 3 shared papers, 2020–2021 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.